ROSEN, LEADING INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN

Core Viewpoint - A class action lawsuit has been announced by Rosen Law Firm on behalf of purchasers of Vistagen Therapeutics, Inc. common stock during the specified Class Period from April 1, 2024, to December 16, 2025, with a lead plaintiff deadline of March 16, 2026 [1]. Group 1: Lawsuit Details - The lawsuit claims that Vistagen provided misleading information regarding its drug fasedienol, which is under development for treating social anxiety disorder, while making overly positive assertions about its trial success based on previous results [5][6]. - Defendants allegedly concealed material adverse facts about the Phase 3 PALISADE-3 trial, leading to investor damages when the true information became public [6]. Group 2: Participation Information - Investors who purchased Vistagen common stock during the Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][7].